Wave has today announced that they have discontinued the clinical program of suvodirsen (designed to skip exon 51 of the dystrophin gene) and are suspending further development of a potential drug designed to skip exon 53 of the dystrophin gene.
Wave has just completed an analysis of dystrophin levels in the muscles of participants in the Phase 1 open label extension trial of suvodirsen. The results show conclusively that the potential drug did not increase the levels of dystrophin in muscle at either a higher or lower dose.
The company is now working with clinical trial sites to discontinue the ongoing trials of suvodirsen and no further doses of suvodirsen will be given, and no further biopsy procedures will be performed. They are also working with clinicians to help them support the families participating in these studies.
We know it will be difficult for our supporters to hear this disappointing news. However, the drug development process means that not all trial drugs will reach the clinic – clinical trials are designed to identify those drugs that are safe and effective. Importantly, Wave has committed to sharing the data from their trials. We’re delighted to hear this, because it means that other researchers, companies and clinicians can learn from these clinical trials.
Any questions
- Call us on 02072508240 or email Neil
Welcome to our new Company Secretary
